Rocket Pharmaceuticals, Inc. /
Renovacor, Inc.
Rocket Pharmaceuticals adds Renovacor to its gene therapy pipeline
- Terms
- Not stated
- Stage
- Closed
What happened
Rocket Pharmaceuticals, Inc. completed its acquisition of Renovacor, Inc. on Dec. 1, 2022. Renovacor shareholders received 0.1763 shares of Rocket common stock for each Renovacor common share.
The acquisition adds REN-001, a gene therapy targeting BAG3-associated dilated cardiomyopathy, to Rocket’s pipeline.
The source
Everything on this page comes from the source below.
Rocket Pharmaceuticals adds Renovacor to its gene therapy pipeline
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly